This inventor holds 29 USPTO granted patents and 5 published patent applications, plus 4 CIPO patents and 8 EPO patents, primarily in Pharmaceutical Formulation. Top assignees: Astrazeneca Ab, Albireo Ab, Elobix Ab. Active years: 2000-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Stockholm, SE (2004)
- Molndal, SE (2007 - 2010)
- Södertälje, SE (2007 - 2014)
- Sodertalje, SE (2011 - 2015)
- Alderley Park, GB (2015)
- Cheshire, GB (2020)
- Johanneshov, SE (2000 - 2023)
Company Filing History:
14 out of 1,534 
6 out of 59 
5 out of 10 
Years Active: 2000-2025
Areas of Expertise:
Title: Innovations of Martin Hans Bohlin
Introduction
Martin Hans Bohlin, located in Södertälje, Sweden, is a prominent inventor with a remarkable portfolio of 27 patents. His work primarily focuses on pharmaceutical innovations, specifically involving the compound odevixibat, aimed at treating various liver diseases.
Latest Patents
Among his recent contributions to the field are two significant patents concerning odevixibat. The first patent, titled "Crystal modifications of odevixibat," relates to new crystal modifications, specifically crystal modifications 1 and 2, alongside a detailed process for preparing crystal modification 1. This invention emphasizes a pharmaceutical composition that utilizes this particular modification in treating a range of medical conditions.
The second patent, named "Pharmaceutical formulation of odevixibat," pertains to a novel pediatric formulation comprised of small particles. This formulation is particularly advantageous for treating liver diseases, including bile acid-dependent conditions such as biliary atresia, progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome (ALGS), and pediatric cholestatic pruritus. Additionally, this patent includes a process for preparing the pharmaceutical formulation, enhancing its clinical utility.
Career Highlights
Throughout his career, Martin has made significant strides while working with esteemed companies such as AstraZeneca and Elobix AB. His experiences in these organizations have helped him refine his innovative approaches to pharmaceutical development.
Collaborations
Martin Hans Bohlin has collaborated with several notable colleagues, including Ingvar Ymen and Robert Lundqvist. These partnerships have fostered a dynamic environment for innovation and have led to the successful development of groundbreaking pharmaceutical solutions.
Conclusion
Martin Hans Bohlin stands out as an influential figure in the field of pharmaceutical innovation. His diligent work continues to advance the treatment options available for liver diseases, showcasing the vital role of inventors in improving healthcare through inventions and patentable innovations.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile